Review of GLP-1 drug pleiotropic effects in heart failure covers anti-inflammatory, cardioprotective, and metabolic mechanisms that benefit HF patients beyond glucose control.
Key findingReview of GLP-1 drug pleiotropic effects in heart failure covers anti-inflammatory, cardioprotective
What the researchers found
Review of GLP-1 drug pleiotropic effects in heart failure covers anti-inflammatory, cardioprotective, and metabolic mechanisms that benefit HF patients beyond glucose control.
Why it matters
Relevant to the expanding applications of peptide-based therapies in medicine.
The numbers in context
Review covers GLP-1 RA effects on MASLD/MASH across inflammation, fibrosis, fat metabolism, and microbiome pathways.
How the study worked
Study methodology detailed in the full publication.
Who was studied
Patients with MASLD/MASH across reviewed clinical and preclinical studies
What this study cannot tell us
Limitations discussed in the full publication.
How to read the evidence
Evidence level based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to the growing body of evidence for peptide therapeutics across medical specialties.
Questions still open
- What are the long-term implications?
- How do results compare to existing evidence?
- What research is needed next?
Common questions
What does this mean for patients?
How reliable is this?
Read the original research
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.
Expert opinion on investigational drugs, 34(3), 169-195
Citation
Alkhouri, Naim; Charlton, Michael; Gray, Meagan; Noureddin, Mazen. (2025). The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.. Expert opinion on investigational drugs, 34(3), 169-195. https://doi.org/10.1080/13543784.2025.2473062